Key facts
- I Peace’s last known valuation is $117.8M (Jun 2021).
- It has raised $47.1M across 5 recorded rounds; the latest was Early Stage VC ($9.7M) in Oct 2024.
- Notable investors include SBI Investment, Hitachi Ventures, Biojent, Maezawa Fund.
- I Peace has filed 5 Form Ds with the SEC since 2016, most recently Feb 2025 ($9.7M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for I Peace
Funding rounds
5 roundsAbout I Peace
Developer of induced pluripotent stem cells designed to help speed the discovery of new personalized medicines. The company's technology streamlines the process of generating and automating the preparation of discrete induced pluripotent stem cells from multiple donors, increasing the available number of clinical-grade lines, enabling the healthcare industry to differentiate induced pluripotent stem cells into appropriate target somatic cells.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2015
- Employees
- 17
- Website
- ipeace.com/
- Ownership
- Privately Held (backing)
I Peace doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in I Peace shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on I Peace in its N-PORT filings yet. We sweep new filings monthly.